Bioverge is changing healthcare startup investing.

Our innovative approach to private healthcare startup investing allows individuals to invest in exclusive deals alongside premier institutions.
Exclusive Access
Deep Domain Expertise
Trailblazing Technology

Our technology empowers
our people.

Bioverge uses predictive models and workflow tools to reengineer the investment experience. Our real estate investment platform is distinguished in its ability to gather, analyze, and leverage information, with radical improvements in workflow efficiency.

Data-Driven Market Selection

Proprietary machine learning models analyze tens of thousands of variables to identify the U.S. real estate markets with the highest potential for price appreciation and income generation: the Cadre 15.1
Learn More

Competitive Deal Selection

Millions of granular data points are ingested into Cadre’s real estate deal management software. These data insights provide a meaningful competitive edge, by enabling Cadre to more accurately identify trending locations and project rent growth. As a result, we can more quickly identify selective investment opportunities through our tech-enabled underwriting process.
Learn More

Next-Generation Asset Management

Cadre developed new technology for its in-house asset management team to more rapidly assess key financial and operating performance metrics, and to optimize the value of our holdings. By automating these complex tasks through technology, our real estate investment professionals are able to better focus on maximizing the value of our investors’ capital and enhancing investor returns.
Learn More

Leverage our deep domain expertise in healthcare.

Bioverge's leadership team has deep healthcare domain expertise and a proven track record of excellence spanning life sciences, technology commercialization, and venture capital. Our relentless drive to deliver compelling returns for our investors powers every investment decision.

Neil J. Littman

Bioverge Founder, Chief Executive Officer, Managing Director

Neil was previously Vice President of Business Development at Notable Labs, an oncology focused startup and Bioverge portfolio company, where he led the development of global corporate partnerships and contributed to the strategic vision. Neil oversaw business development at Notable through the successful completion of the company’s $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets.

Prior to Notable, Neil was a member of the Executive Leadership Team and Director of Business Development at the California Institute for Regenerative Medicine (CIRM). As part of CIRM’s leadership team, Neil helped develop the five-year strategic plan for managing and deploying CIRM’s $3 billion across the organization’s discovery, translational, and clinical stage stem cell and regenerative medicines programs. At CIRM, Neil was Head of the Therapeutics Group and oversaw a team responsible for managing over 40 clinical stage therapies totaling over $500 million of CIRM investment, including Forty Seven, Inc. (acquired by Gilead for $4.9B), Orchard Therapeutics (Nasdaq: ORTX), Cellular Dynamics International (acquired by Fujifilm for $307M), Sangamo Therapeutics, Inc. (Nasdaq: SGMO), Poseida Therapeutics, Inc. (Nasdaq: PSTX), and others.

Prior to managing the Therapeutics Group, Neil oversaw the Strategic Infrastructure Group at CIRM, managing a portfolio of $125 million supporting infrastructure programs including: $30 million Stem Cell Center (partnership with IQVIA); $24 million Alpha Stem Cell Clinical Network (partnership with UCLA, UCSD, City of Hope, UC Irvine); $32 million iPSC Bank (partnership with Fujifilm); $40 million Genomics Center of Excellence (partnership with Stanford).

Prior to CIRM, Neil was a healthcare investment banker at Thomas Weisel Partners and Deutsche Bank, working on transactions totaling over $1 billion. His primary focus was on strategic advisory and public and private financings.

Neil received a Master of Science in Biotechnology from The Johns Hopkins University, and a Bachelor of Arts in Molecular, Cellular and Development Biology from the University of Colorado, Boulder.

Rick Gibb

Bioverge Founder, Chief Operating Officer, Managing Director

Rick previously worked at Stanford University’s Office of the CFO as a Senior Venture Fund Analyst where he was involved in the management and oversight of the President’s Venture Fund and Stanford-StartX Fund. Across both of these funds, Rick was primarily involved with investment sourcing, due diligence, and portfolio management, investing $450M in aggregate across more than 400 companies. This further included providing ongoing support by connecting them to elite talent, fundraising opportunities and strategic partnerships, as well as stewarding long-term strategic plans and operating roadmaps to achieve commercialization, a stronger innovation pipeline, and enhanced product-market fit.

Notable highlights include leading seed-stage investments into Personalis (precision medicine and cancer genomics company; co-investors:Lightspeed; NASDAQ: PSNL), Kodiak Sciences (antibody therapies to treat and prevent blindness; NASDAQ: KOD), Oculeve (ocular stimulation to treat dry eye disease; acquired by Medtronic), Genapsys(desktop DNA sequencing), HeartFlow (real-time digital modeling of coronary arteries; co-investors: Medtronic, USVP, GE Ventures; $1.5B+ valuation), and Orca Bio (cellular therapies to treat cancer and autoimmune disorders; co-investors: Lightspeed, Data Collective, 8VC).

Prior to this, Rick was a part of the Licensing team at Stanford University’s Office of Technology Licensing (OTL). The OTL receives and evaluates over 500 invention disclosures each year to assess their commercial feasibility and potential. Royalties from successful licensing are collected and distributed to the inventors, their departments and schools. At the OTL, he managed a portfolio of 300+ technologies across their full lifecycle to support them with critical expertise in IP strategy, marketing, business development, licensing, fundraising and commercialization.

Rick holds a Master’s Degree in Biotechnology from The Johns Hopkins University, and graduated from Rice University with a B.S. in Bioengineering and Biomedical Engineering.


Lorem ipsum

Sonia Arrison

Venture Partner, Portfolia;
Founder at 100 Plus Capital;
Board Chair at The Alliance for Longevity Initiatives

Brenden Boot, M.D.

Brigham and Women's Hospital; Assistant Professor Harvard Medical School

Mark Chao, Ph.D.

Co-founder and CEO, TenSixteen

Dave Chisholm

Partner Manager, Dassault Systèmes

Kevin Coker, JD, MPH, MS

Co-founder & CEO,
Proxima Clinical Research

Curt Herberts

President & COO,
Kriya Therapeutics

Brock Reeve, Ph.D.

Co-founder & CEO,
Eos BioInnovation;
Executive Director, Harvard Stem Cell Institute

Greg Simon

Biden Cancer Initiative;
Executive Director,
White House Cancer Moonshot Task Force

David Stubbs

Head of European Health Care at RaymondJames Financial International, Ltd.

Joseph Wu, M.D. Ph.D.

Professor & Director of Stanford Cardiovascular Institute; President-Elect of American Heart Association; Co-founder, Greenstone Biosciences

Trusted by leading institutional investors.

Some of the world’s most sophisticated and experienced institutions are Cadre clients. We continue to meet their rigorous operational, financial, and governance standards in the same real estate funds and deal-by-deal offerings we deliver to individuals and advisors.

Backed by the best.

Cadre’s innovative commercial real estate investment platform has the financial backing of some of the largest and most respected venture capital firms, investment firms, real estate companies, and industry veterans.

Building a more inclusive healthcare ecosystem.

We invite you to join our mission to make healthcare venture capital more accessible, transparent and affordable to a greater number of investors.
Bioverge has a robust network of minority real estate developers and operators. We are building business partnerships with minority-owned depository institutions (“MDIs”). As a minority-owned and -led company, our diversity, equity and inclusion (DEI) strategy is core to all we do, and includes initiatives to:


investment capital to back minority-owned real estate operating partners.


corporate cash with minority-owned depository institutions.


with minority-owned banks to participate in financing our properties.


a consistent number of affordable rental units for families within our multifamily properties.

Sign Up
We invite you to join our mission to make commercial real estate more accessible, transparent and affordable to a greater number of investors.

In the Press, The Bioverge Podcast, and Latest Research

Join the team.

Do you have the talent, imagination, and passion to help bring profound change to healthcare investing?

Check out our current job openings.
Important Disclosures
Private Securities
Investments in private offerings are speculative and involve a high degree of risk. Investments in private offerings are not bank deposits and therefore are not insured by the FDIC or guaranteed by any other party. Investors must be qualified as an accredited investor to participate in private offerings and you may be required to verify your status as an accredited investor. No securities commission or regulatory authority has recommended or approved any investment or the accuracy or completeness of any of the information or materials provided by or through us.
Not Advice
This communication is not to be construed as investment, tax, or legal advice in relation to the relevant subject matter; investors must seek their own legal or other professional advice before making any investment to determine whether an investment is suitable for them.
Performance Not Guaranteed
Past performance is no guarantee of future results. Any historical returns, expected returns, or probability projections are not guaranteed and may not reflect actual future performance.
Risk of Loss
All investments involve a high degree of risk and may result in partial or total loss of your investment.
Liquidity Not Guaranteed
Investments offered by Bioverge are illiquid and there is never any guarantee that you will be able to exit your investments on the Secondary Market or at what price an exit (if any) will be achieved.
Not an Offer to Sell or Solicitation to Buy
The information presented on this Website does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Bioverge. Any such offer would only be made through of a prospectus, private placement memorandum, subscription agreement or similar documents. This Website is subject to material updating, revision and further amendment.
Conduct Your Own Due Diligence
This information is not intended to provide the sole basis for your evaluation of Bioverge. You should conduct your own due diligence of Bioverge and independently verify the information contained below before proceeding further with any investment in or other transaction with Bioverge. Our officers will make themselves available to answer any questions that you may have regarding our company, its business, operations and prospects should you decide to proceed further with an investment or other transaction with Bioverge.
Forward Looking Statements
The information set forth below includes statements, estimates, projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectations. Back